Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.74 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.74 |
| ▸ | PDE4A | P27815 | 15/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.74 |
| ▸ | TNF | P01375 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537159 | 0.86 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DTNF | |
| SCHEMBL1566155 | 0.85 | PDE4B (0.81) | PDE4BPDE4CPDE4APDE4DTNF | |
| SCHEMBL1193944 | 0.85 | PDE4B (0.81) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1194547 | 0.85 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DTNF | |
| SCHEMBL9977547 | 0.85 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DTNF | |
| SCHEMBL29603817 | 0.85 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DTNF | |
| SCHEMBL6099935 | 0.85 | PDE4A (0.74) | PDE4BPDE4CPDE4APDE4DTNF | |
| SCHEMBL30678828 | 0.85 | PDE4B (0.79) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL31062950 | 0.85 | PDE4B (0.79) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL7741527 | 0.84 | TNF (0.88) | PDE4BPDE4CPDE4APDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305248-B1 | Substituted phenethylsulfones and method of reducing tnf-alpha levels | CELGENE CORP (US) | 2013-05-08 | — | — | EP | claimed |
| EP-2305248-A1 | Substituted phenethylsulfones and method of reducing tnf-alpha levels | CELGENE CORPORATION (US) | 2011-04-06 | — | — | EP | claimed |
| EP-1752148-A2 | Substituted phenethylsulfones for the treatment of inflammatory, infectious, immunological or malignant disease | CELGENE CORPORATION (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1126839-B1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF-ALPHA AND PDE-IV LEVELS | CELGENE CORP (US) | 2007-01-03 | — | — | EP | claimed |
| US-6020358-A | REDUCING TUMOR NECROSIS FACTOR CONCENTRATION | CELGENE CORPORATION (US) | 2000-02-01 | — | — | US | claimed |
| EP-2305248-B1 | Substituted phenethylsulfones and method of reducing tnf-alpha levels | CELGENE CORP (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8263637-B2 | Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide | CELGENE CORPORATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | CELGENE CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2305248-A1 | Substituted phenethylsulfones and method of reducing tnf-alpha levels | CELGENE CORPORATION (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20110038832-A1 | METHOD FOR TREATMENT OF MACULAR DEGENERATION USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE | CELGENE CORPORATION | 2011-02-17 | — | — | US | disclosed |
| EP-2258363-A1 | Compositions for treatment of cancers | CELGENE CORPORATION (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7842691-B2 | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide | CELGENE CORPORATION (US) | 2010-11-30 | — | — | US | disclosed |
| WO-2003086373-A1 | METHODS FOR IDENTIFICATION OF MODULATORS OF ANGIOGENESIS, COMPOUNDS DISCOVERED THEREBY, AND METHODS OF TREATMENT USING THE COMPOUNDS | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1242082-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORPORATION (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020054899-A1 | Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders | CELGENE CORP. | 2002-05-09 | — | — | US | disclosed |
| EP-1126839-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF ALPHA LEVELS | CELGENE CORPORATION (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2001043743-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORP. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000025777-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNFαLEVELS | CELGENE CORPORATION (US) | 2000-05-11 | — | — | WO | disclosed |
| US-6020358-A | REDUCING TUMOR NECROSIS FACTOR CONCENTRATION | CELGENE CORPORATION (US) | 2000-02-01 | — | — | US | disclosed |
| US-6011050-A | Substituted phenethylsulfones and method of reducing TNFα levels | CELGENE CORPORATION (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165292-A2 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE | IL2, HDGF, VEGFA | PDE4B 1724/4885PDE4C 1641/4885PDE4A 1843/4885 |
| US-20110038832-A1 | METHOD FOR TREATMENT OF MACULAR DEGENERATION USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE | ALDH1A2, MTNR1A, MTNR1B | PDE4B 438/4885PDE4C 452/4885PDE4A 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.